Rise and shine, everyone, another busy day is on the way. The Pharmalot campus, in fact, is humming thanks to some repair work to the castle, although our short person is sleeping in, since this constitutes a spring break on the calendars kept by some institutions of higher learning. As for us, we can see a steady flow of flurries outside our window, and we are keeping warm with another cup of stimulation. Our choice today is blueberry cobbler. Please feel free to join us. Meanwhile, we have assembled the latest list of interesting items for you to peruse. We hope your days goes well and you conquer the world. And of course, do keep in touch. …
Under mounting pressure, Novo Nordisk plans to cut U.S. list prices for several insulin products by up to 75%, the latest big drugmaker to take such a step in response to a years-long outcry over the cost of the diabetes treatments, STAT writes. The company plans to cut the list price of its NovoLog insulin by 75% and the prices for Novolin and Levemir by 65% starting in January 2024. Novo will also lower prices for its unbranded insulin products to match the reduced price of its corresponding brand-name insulin treatments. The move comes after Eli Lilly recently announced plans to lower list prices for its most commonly prescribed insulin products by 70%,
In an unexpected move, the Veterans Health Administration decided that it will widely cover a new Alzheimer’s treatment, even as Medicare has decided to wait for additional data about the medicine before taking the same step, STAT reports. The VA will provide coverage to veterans who meet agency criteria for using the medicine — called Leqembi — as well as stipulations on the product labeling, according to Eisai, which is partnering with Biogen to market the treatment. About 80% to 90% of veterans who clear these hurdles may be eligible for the treatment, but the exact number is uncertain, according to an Eisai spokesperson.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect